Your browser is no longer supported. Please, upgrade your browser.
Settings
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-0.77 Insider Own2.30% Shs Outstand344.90M Perf Week5.70%
Market Cap12.16B Forward P/E3.25 EPS next Y10.86 Insider Trans-14.06% Shs Float335.92M Perf Month30.22%
Income-266.20M PEG- EPS next Q1.37 Inst Own66.80% Short Float5.36% Perf Quarter-59.07%
Sales10.50B P/S1.16 EPS this Y-129.00% Inst Trans20.41% Short Ratio0.72 Perf Half Y-67.82%
Book/sh18.49 P/B1.91 EPS next Y23.59% ROA- Target Price63.67 Perf Year-83.53%
Cash/sh1.73 P/C20.35 EPS next 5Y12.25% ROE- 52W Range25.27 - 263.81 Perf YTD-65.32%
Dividend- P/FCF- EPS past 5Y6.10% ROI- 52W High-86.64% Beta0.25
Dividend %- Quick Ratio- Sales past 5Y54.80% Gross Margin74.80% 52W Low39.49% ATR2.55
Employees16800 Current Ratio- Sales Q/Q22.30% Oper. Margin14.60% RSI (14)45.54 Volatility5.41% 8.00%
OptionableYes Debt/Eq- EPS Q/Q-162.30% Profit Margin-2.50% Rel Volume0.58 Prev Close34.92
ShortableYes LT Debt/Eq- EarningsMay 05 BMO Payout- Avg Volume25.19M Price35.25
Recom2.90 SMA208.55% SMA50-26.16% SMA200-72.28% Volume14,486,795 Change0.95%
Apr-12-16Reiterated RBC Capital Mkts Sector Perform $69 → $65
Apr-11-16Reiterated Rodman & Renshaw Buy $118 → $105
Mar-21-16Downgrade Mizuho Neutral → Underperform $70 → $18
Mar-21-16Downgrade Barclays Overweight → Equal Weight $135 → $34
Mar-16-16Reiterated Stifel Buy $200 → $65
Mar-16-16Reiterated Rodman & Renshaw Buy $150 → $118
Mar-16-16Reiterated RBC Capital Mkts Sector Perform $85 → $69
Mar-16-16Reiterated Canaccord Genuity Hold $75 → $40
Mar-16-16Downgrade Nomura Buy → Neutral $175 → $60
Mar-16-16Downgrade CIBC Sector Perform → Sector Underperform
Mar-15-16Downgrade Piper Jaffray Neutral → Underweight
Mar-08-16Reiterated Mizuho Neutral $112 → $70
Mar-02-16Downgrade Canaccord Genuity Buy → Hold $125 → $75
Mar-01-16Downgrade RBC Capital Mkts Outperform → Sector Perform $194 → $85
Feb-29-16Downgrade TD Securities Buy → Hold
Feb-19-16Initiated Wells Fargo Underperform
Feb-16-16Initiated Rodman & Renshaw Buy $150
Jan-07-16Reiterated Mizuho Neutral $130 → $112
Jan-06-16Resumed Susquehanna Neutral $105
Dec-17-15Downgrade Mizuho Buy → Neutral $111 → $130
Apr-28-16 03:44PM  Sen. Collins: I Hope Valeant Lowers Its Prices Bloomberg
03:43PM  Sen. Collins: I Hope Valeant Lowers Its Prices at Bloomberg
02:19PM  Ackmans testimony suggests hes in charge at Valeant at MarketWatch
01:56PM  Now we have a clue just how close Valeant came to the brink Business Insider
01:51PM  Board Shakeup Lifts Valeant (VRX) Shares As Jim Cramer Sees Pharma M&A on the Rise at TheStreet
01:19PM  The new Valeant CEO's pay package is putting the company in serious danger Business Insider
01:11PM  Why Are Investors Piling Into These Surging Stocks? at Insider Monkey
12:52PM  Valeant Revisits The Same Flawed Pay Math at Bloomberg
12:46PM  Heres how much money it took for Perrigos ex-CEO to leave for Valeant at MarketWatch
12:40PM  Valeant Testimony Uncovers Core Problem: Drug Companies Soaking Taxpayers Yahoo Finance Contributors
12:10PM  Valeant Pharmaceuticals 10-K for 2015: The Wait Continues Market Realist
12:09PM  Analysts Ratings of Valeant Pharmaceuticals before 1Q16 Earnings Market Realist
11:51AM  [$$] Valeant: Swapping Scandal for Growing Pains at The Wall Street Journal
11:48AM  Valeant's Wild Ride May Soon Be Over at TheStreet
10:49AM  Valeant Pharmaceuticals' Mea Culpa May Throw the Entire Industry Under the Bus at Motley Fool
10:39AM  Valeant Said to Replace Up to Five Board Members This Week at Bloomberg
09:10AM  Herding, Hearings and Proxy Fights at Bloomberg
08:33AM  Report: Ingram could leave Valeant board at American City Business Journals
08:26AM  Bill Ackman Is The 'Unofficial Leader Of A Thundering Herd' That Lost Billions Of Dollars Benzinga
07:30AM  Valeant's New CEO Joe Papa Will Make Over $500 Million If Stock Rockets To $270 By 2020 at Forbes
07:29AM  Valeants New CEO Could Pull in $500 Million at Fortune
07:19AM  What to expect from Valeant earnings at MarketWatch
01:20AM  JANBX: Overview of Janus Balanced Fund at Investopedia
12:37AM  Valeant Pharmaceuticals to Make Sweeping Changes to Board at The Wall Street Journal
Apr-27-16 10:14PM  Valeants Michael Pearson Admits Aggressive Drug-Price Increases Were a Mistake at The Wall Street Journal
09:54PM  Valeant to name four new directors as soon as Friday: WSJ Reuters
09:52PM  [$$] Valeant to Make Sweeping Changes to Board at The Wall Street Journal
09:48PM  Valeant's `Mistakes' Raised Profit, Destroyed Value, Ackman Says at Bloomberg
09:16PM  Valeant to name four new directors as soon as Friday -WSJ Reuters
08:55PM  [$$] Valeant's Pearson Admits Aggressive Drug-Price Increases Were a Mistake at The Wall Street Journal
08:27PM  Valeant Discloses Pay for New CEO at The Wall Street Journal
07:48PM  Valeant to pay new CEO Papa base salary of $1.5 million Reuters
07:46PM  Elizabeth Warren totally gets Valeant Business Insider
07:42PM  Lawmakers blast Valeant for price-gouging tactics AP
07:37PM  [$$] Bill Ackman admits fault in Valeant investment at Financial Times
07:27PM  Valeant CEO tells Senate committee drug price increases were too aggressive at MarketWatch
07:27PM  Ackman, Valeant pledge reforms after spiking drug prices Reuters
07:02PM  Now we know why Valeant's new CEO took the job, and it seems politicians are upset about it Business Insider
06:49PM  Valeant's New CEO Joe Papa Will Make Over $500 Million If Stock Rockets To $270 By 2020 at Forbes
06:49PM  Ackman: Plan to Discuss Drug Prices With Valeant Board Bloomberg
06:40PM  Valeant Drug Pricing Hearing --- Recap at The Wall Street Journal
06:21PM  Valeant to pay new CEO Papa base salary of $1.5 mln Reuters
06:19PM  Bill Ackman: Valeants Drug Price Hikes Hurt America at Fortune
06:14PM  Senate told Valeant drug price hikes hurt patients at USA TODAY
05:59PM  Business Highlights AP
05:56PM  Why Dan Loeb fears this is 1st inning of a washout in hedge funds at MarketWatch
05:37PM  Valeant Sets Incoming CEO Joe Papa's Pay at $67.4 Million at Bloomberg
05:36PM  Ackman: 'A Lot Is Going to Change' at Valeant at TheStreet
05:27PM  Ackman: It's Very Hard to Find Out the Prices for Drugs Bloomberg
05:25PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial EDGAR Online
04:54PM  Will Joseph Papa Be Able to Change Valeant? Bloomberg
04:44PM  Tweets on the Street: Shkreli Tunes In for Valeant Hearing; Trump's Foreign Policy at TheStreet
04:39PM  LIVE: Bill Ackman and Valeant execs get grilled by angry senators Business Insider
04:00PM  Valeant Pharmaceuticals And Bill Ackman Have Their Day In Washington at Forbes
03:37PM  Valeant CEO to tell Senate he regrets raising heart drug prices Reuters
03:34PM  The prepared statements from Valeant's Senate hearing are already making us cringe Business Insider
03:33PM  Wells Fargo analyst: Why a new CEO won't save Valeant at CNBC
03:31PM  Ackman, Valeant Offers Apologies, Concessions at Drug Hearing at Bloomberg
02:48PM  Mr. Ackman Goes to Washington to Defend Drug Pricing at Valeant at TheStreet
02:01PM  Elizabeth Warren gets a go at hedge fund billionaire Bill Ackman Business Insider
01:44PM  [$$] Daniel Loeb warns of hedge fund 'killing field' at Financial Times
01:00PM  Wednesday links: liking the work itself Yahoo Finance Contributors
12:59PM  Valeant's CEO is heading for a grilling, but it looks like Congress isn't discouraging drug-price hikes Business Insider
12:51PM  Wall Street dropped a bomb on Valeant right before the company's Senate hearing Business Insider
11:07AM  Bill Ackman, Valeant's Pearson and Elizabeth Warren, Oh My! at The Wall Street Journal
10:10AM  Fireworks Expected at Valeant Hearing on Capitol Hill Bloomberg
09:00AM  Exclusive: The Woman Behind the Female Viagra Has a New Venture at Fortune
07:20AM  Valeant Was `Too Aggressive' in Pricing, CEO to Tell Senate at Bloomberg
12:19AM  Valeant Was Too Aggressive in Raising Drug Prices, CEO Says at The Wall Street Journal
12:10AM  Valeant Was Too Aggressive in Raising Drug Prices, CEO Says at The Wall Street Journal
12:07AM  [$$] Bill Miller Spies Value in Valeant Shares at The Wall Street Journal
12:00AM  Valeant CEO to tell U.S. Senate he regrets raising heart drug prices Reuters
Apr-26-16 09:01PM  This Mega-Fund Just Gobbled Up Valeant's Shares -- Should You, Too? at Motley Fool
06:20PM  A Bruising Year Doesn't Follow Bill Ackman Into Canadian Pacific's Boardroom at Forbes
05:08PM  Senate hearing into Valeant includes top hedge fund investor AP
05:01PM  Ackman to Testify About Valeant Before Senate Gurufocus
03:02PM  Valeant (VRX) Stock Up Despite Records Withholding Speculation at TheStreet
02:47PM  Senate Calls for Former Valeant CFO to Testify at Hearing at Fortune
02:19PM  Bill Miller sees opportunity in Valeant shares where others see chaos at MarketWatch
01:59PM  House Democrats question if Valeant is withholding records Reuters
01:58PM  U.S. House Democrats question if Valeant is withholding records Reuters
01:41PM  Bill Miller Nabs Valeant Shares, Spying Opportunity Where Others See Chaos at The Wall Street Journal
01:36PM  Perrigo's CEO Resigns, Trims 2016 Outlook, Stock Tumbles Zacks
01:06PM  U.S. House Democrats question if Valeant is wrongfully withholding records Reuters
12:25PM  Ackman, ExxonMobil and a $1 trillion bubble Business Insider
12:05PM  13D Monitor Conference Notes Yahoo Finance Contributors
11:55AM  Congress just got a bunch of documents Valeant was withholding, and there's a memo about them circulating on Capitol Hill Business Insider
11:43AM  Senate panel to question investor Bill Ackman about drugmaker Valeant at Los Angeles Times
10:08AM  Valeant ex-CFO Schiller, CEO Pearson and Bill Ackman to testify at Senate hearing at MarketWatch
09:55AM  Bill Ackman goes to Congress Business Insider
09:01AM  One Mutual Fund That Valeant Pharmaceuticals International Inc. Took Down With It at Motley Fool
08:54AM  New Valeant CEO Papa may step in midway through accounting madness at MarketWatch
08:14AM  Ackman to Testify With Pearson at Senate Drug-Pricing Hearing at Bloomberg
05:00AM  New Valeant CEO Papa Trades Challenge at Perrigo for Fresh One at Bloomberg
12:48AM  [$$] CEO Exits Show That Room at the Top Can Be Lonely at The Wall Street Journal
12:47AM  [$$] Valeant Names Joseph Papa as New CEO at The Wall Street Journal
Apr-25-16 06:27PM  Valeant names Papa CEO after he resigns from Perrigo Reuters
05:35PM  Embattled drugmaker Valeant taps Papa as new CEO at USA TODAY
05:15PM  Stocks End Lower as Earnings Weigh Morningstar
05:06PM  Stocks Quiet Ahead Of Fed; How Will Apple Fare? at Investor's Business Daily
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer. It also provides Zovirax, an antiviral for recurrent herpes labialis and initial genital herpes; Syprine to treat patients with Wilson's disease; Elidel to treat atopic dermatitis; Prolensa for inflammation and pain following cataract surgery; Duromine, a weight loss drug; and Lotemax gel for post-operative inflammation and pain. In addition, the company offers PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; ReNu Multiplus to lubricate and rewet soft contact lenses; Biotrue for healthy contact lens wear; Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; AntiGrippin for acute respiratory and respiratory viral diseases, and influenza; and Bedoyecta, a vitamin B complex product. Further, it provides SofLens daily disposable contact lenses; PureVision, a contact lens; various ophthalmic surgical products; Biotrue ONEday lens; medical device systems for aesthetic applications; and Bausch + Lomb Ultra, a contact lens. Additionally, the company offers Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Cardizem CD to treat hypertension and angina; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pearson J. MichaelChief Executive OfficerNov 05Sale78.481,297,399101,825,9701,514,664Nov 09 05:24 PM
Farmer Ronald HaroldDirectorOct 21Buy181.601,500272,39515,532Oct 22 05:09 PM
Farmer Ronald HaroldDirectorAug 26Buy220.00500110,0002,000Aug 27 04:33 PM
Farmer Ronald HaroldDirectorAug 21Buy224.971,000224,9731,500Aug 25 04:47 PM
Rosiello Robert L.EVP, Chief Financial OfficerJul 31Buy257.25704181,104441,675Aug 03 04:54 PM
Rosiello Robert L.EVP, Chief Financial OfficerJul 30Buy253.997,1711,821,362440,971Aug 03 04:54 PM
Rosiello Robert L.Executive Vice PresidentJun 12Buy232.5112,9002,999,37912,900Jun 16 04:01 PM
UBBEN JEFFREY WDirectorJun 10Sale220.244,200,000925,011,6131,059,793Jun 12 07:23 PM
Farmer Ronald HaroldDirectorJun 09Buy232.05500116,025500Jun 10 05:02 PM
Farmer Ronald HaroldDirectorJun 08Buy289.20500144,60035,426Jun 10 05:02 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 02Option Exercise51.0114,900760,04951,575Jun 03 05:45 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 02Sale238.0037,9009,020,31813,675Jun 03 05:45 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 01Option Exercise51.011005,10136,775Jun 03 05:45 PM
Mirovsky PavelEVP, Pres. & GM Valeant EMENAJun 01Sale240.0010024,00036,675Jun 03 05:45 PM
Whitaker Anne ClemDirectorMay 26Buy234.677,5001,760,0007,500May 27 04:29 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMay 05Option Exercise6.1021,807133,02364,994May 06 05:51 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMay 04Option Exercise25.4290,9382,311,644134,125May 06 05:51 PM
Chai-Onn Robert RoswellEVP, CLO, General CounselMay 04Sale222.5490,93820,237,44343,187May 06 05:51 PM